Sonnet BioTherapeutics Holdings, Inc. - Common Stock (SONN)
6.4800
+0.9400 (16.97%)
NASDAQ · Last Trade: Sep 16th, 5:21 PM EDT
Detailed Quote
Previous Close
5.540
Open
5.960
Bid
6.690
Ask
6.700
Day's Range
5.690 - 7.900
52 Week Range
1.080 - 19.30
Volume
5,118,979
Market Cap
43.77M
PE Ratio (TTM)
-0.9178
EPS (TTM)
-7.1
Dividend & Yield
N/A (N/A)
1 Month Average Volume
958,120
Chart
About Sonnet BioTherapeutics Holdings, Inc. - Common Stock (SONN)
Sonnet Biotherapeutics Holdings Inc is a biotechnology company focused on the development of innovative therapies for various diseases, particularly in the field of immuno-oncology. The company leverages its proprietary technology platform to create biologic drugs that aim to harness the body's immune system to target and eliminate cancer cells. Through a combination of advanced engineering and scientific expertise, Sonnet is working to deliver novel treatments that could provide meaningful benefits to patients in need, addressing unmet medical needs in oncology and other therapeutic areas. Read More
NEW YORK, July 19, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
U.S. stocks traded mostly flat on Monday as investors reacted to President Donald Trump's announcement of a 30% tariff on all imports from the EU and Mexico.
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Sonnet BioTherapeutics, Inc. (NASDAQ: SONN) and Rorschach I LLC is fair to Sonnet shareholders. Upon completion of the proposed transaction, Sonnet shareholders will own approximately 1% of the combined company.
